Similarly, the drug canagliflozin, which stimulates HO-1 expression and blocks UGTA1A activity [147,169], raises circulating levels of bilirubin in patients with type 2 diabetes, providing further validation for this strategy [170,171]. This evidence concerns the gene HMOX1 and type 2 diabetes mellitus.